D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia.
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
07
2021
accepted:
31
01
2022
entrez:
3
3
2022
pubmed:
4
3
2022
medline:
9
3
2022
Statut:
epublish
Résumé
Health care workers have had a challenging task since the COVID-19 outbreak. Prompt and effective predictors of clinical outcomes are crucial to recognize potentially critically ill patients and improve the management of COVID-19 patients. The aim of this study was to identify potential predictors of clinical outcomes in critically ill COVID-19 patients. The study was designed as a retrospective cohort study, which included 318 patients treated from June 2020 to January 2021 in the Intensive Care Unit (ICU) of the Clinical Hospital Center "Bezanijska Kosa" in Belgrade, Serbia. The verified diagnosis of COVID-19 disease, patients over 18 years of age, and the hospitalization in ICU were the criteria for inclusion in the study. The optimal cutoff value of D-dimer, CRP, IL-6, and PCT for predicting hospital mortality was determined using the ROC curve, while the Kaplan-Meier method and log-rank test were used to assess survival. The study included 318 patients: 219 (68.9%) were male and 99 (31.1%) female. The median age of patients was 69 (60-77) years. During the treatment, 195 (61.3%) patients died, thereof 130 male (66.7%) and 65 female (33.3%). 123 (38.7%) patients were discharged from hospital treatment. The cutoff value of IL-6 for in-hospital death prediction was 74.98 pg/mL (Sn 69.7%, Sp 62.7%); cutoff value of CRP was 81 mg/L (Sn 60.7%, Sp 60%); cutoff value of procalcitonin was 0.56 ng/mL (Sn 81.1%, Sp 76%); and cutoff value of D-dimer was 760 ng/mL FEU (Sn 63.4%, Sp 57.1%). IL-6 ≥ 74.98 pg/mL, CRP ≥ 81 mg/L, PCT ≥ 0.56 ng/mL, and D-dimer ≥ 760 ng/mL were statistically significant predictors of in-hospital mortality. IL-6 ≥ 74.98 pg/mL, CRP values ≥ 81 mg/L, procalcitonin ≥ 0.56 ng/mL, and D-dimer ≥ 760 ng/mL could effectively predict in-hospital mortality in COVID-19 patients.
Identifiants
pubmed: 35237386
doi: 10.1155/2022/8997709
pmc: PMC8884120
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
IL6 protein, human
0
Interleukin-6
0
fibrin fragment D
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8997709Informations de copyright
Copyright © 2022 Marija Milenkovic et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2245-2249
pubmed: 33395786
Thromb Res. 2020 Dec;196:67-74
pubmed: 32853978
J Med Virol. 2022 Jan;94(1):197-204
pubmed: 34427922
Medicine (Baltimore). 2020 Nov 13;99(46):e23186
pubmed: 33181697
Eur Respir J. 2020 Sep 24;56(3):
pubmed: 32907886
Eur Rev Med Pharmacol Sci. 2021 Jan;25(2):1135-1145
pubmed: 33577070
Med Mal Infect. 2020 Jun;50(4):332-334
pubmed: 32243911
Immunology. 2020 Jul;160(3):261-268
pubmed: 32460357
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725
Clin Infect Dis. 2022 Jan 29;74(2):254-262
pubmed: 34013339
J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8
pubmed: 33010257
Postgrad Med. 2021 Jan;133(1):20-27
pubmed: 32921198
Med Sci Monit. 2021 May 12;27:e932361
pubmed: 33976103
J Med Virol. 2021 Feb;93(2):934-944
pubmed: 32706426
Exp Hematol Oncol. 2021 May 31;10(1):34
pubmed: 34059141
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
EClinicalMedicine. 2020 Jul 31;26:100475
pubmed: 33089115
Arch Pathol Lab Med. 2020 Oct 1;144(10):1223-1229
pubmed: 32551814
Crit Care Med. 2020 Sep;48(9):1358-1364
pubmed: 32467443
Med Microbiol Immunol. 2021 Feb;210(1):33-47
pubmed: 33219397
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
J Infect. 2021 Jun;82(6):e24-e26
pubmed: 33745917
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Int J Med Sci. 2020 May 18;17(9):1281-1292
pubmed: 32547323
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32544099
Thromb Res. 2020 Nov;195:219-225
pubmed: 32777639
J Pharm Pract. 2021 Mar 15;:897190021998502
pubmed: 33719698
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Thromb Res. 2020 Dec;196:99-105
pubmed: 32853982
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Infect Genet Evol. 2020 Nov;85:104502
pubmed: 32798769
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Semin Thromb Hemost. 2020 Oct;46(7):777-780
pubmed: 32396963
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Allergy. 2021 Feb;76(2):533-550
pubmed: 32662525